Fair Value Calculator Fair Value Calculator
EN DE

1334 (1334) Fair Value & Analysis

Industrials · Market cap HK$600M

1 1334 1334 · HK
PriceHK$1.20
Fair ValueHK$0.2400
Upside-80.0%
Quality33/100
Evidence: Medium Range HK$0.1800 – HK$0.3000

Fair value as of: Jul 2, 2026

From 14 valuation models · updated today

Share price −44.4% over the past month.

Price vs Fair Value (12 months)

HK$2.56 HK$0.9000 Fair Value HK$0.2400 Jun 2025 Jun 2026

12‑month range HK$0.9000 – HK$2.56 · fair‑value band HK$0.1800 – HK$0.3000 · the HK$1.20 price screens above the HK$0.2400 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1334 (1334) currently trades at HK$1.20, while our model-based Fair Value estimate is HK$0.2400 — implying the stock looks roughly 80.0% overvalued today. We read business quality at 33/100 (below-average quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, 1334 generated revenue of HK$502M at a net margin of 1.0%. Revenue grew 59.7% year over year. It earns a return on equity of 1.2%. Net debt stands at HK$89.8M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$502M
Revenue growth (YoY) +59.7%
Net margin 1.0%
Return on equity 1.2%
Free cash flow −HK$50.7M FY2025
P/E ratio 120.0
More key figures
Operating margin 12.0%
EPS (TTM) HK$-0.0800
Net debt HK$89.8M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1334 reported revenue of HK$502M in FY2025 versus HK$248M in FY2021, a compound +19.3%/yr. Reported net income was HK$5.0M in FY2025, compounding −21.8%/yr from FY2021.

Revenue +19.3%/yr
FY21 HK$248M
FY22 HK$419M
FY23 HK$544M
FY24 HK$444M
FY25 HK$502M
Net income −21.8%/yr
FY21 HK$13.4M
FY22 HK$36.5M
FY23 HK$55.2M
FY24 HK$10.3M
FY25 HK$5.0M

Is 1334 fairly valued? → Check now

Similar stocks

6 more Specialty Industrial Machinery stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock Price Fair Value vs Fair Value
GE Vernova Inc GEV $963.33 $315.30 -67%
SIEGY SIEGY $155.06 $89.54 -42%
SMAWF SMAWF $307.12 $176.28 -43%
SMNS SMNS C$31.76 C$22.85 -28%
SIE SIE €279.00 €140.38 -50%
Schneider Electric S.E. SBGSF $334.00 $148.44 -56%

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is 1334 (1334) undervalued?
As of Jul 2, 2026, our model estimates a fair value of HK$0.2400 versus a price of HK$1.20 — about −80% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 1334?
Our model-based fair value for 1334 is HK$0.2400 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$1.20.
What is the quality score of 1334?
1334 has a Quality Score of 33/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of 1334 (1334)?
1334 reported trailing-twelve-month revenue of about HK$502M (latest available figure, as of Jul 2, 2026).
What is the net profit margin of 1334?
The net profit margin of 1334 is about 1.0%, meaning it keeps roughly 1.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.